Recently, Lilin® Bortezomib for Injection (specifications: 1.0mg, 3.5mg) produced by Shandong New Era Pharmaceutical Co., Ltd., a subsidiary of Lunan Pharmaceutical Group , was approved for marketing by the National Medical Products Administration and is considered to have passed the consistency evaluation of generic drug quality and efficacy. The approval numbers are: National Drug Approval Number H20264387 and National Drug Approval Number H20264388.

The active ingredient in this product is bortezomib, a reversible inhibitor of chymotrypsin-like activity of the 26S proteasome in mammalian cells. It induces tumor cell apoptosis by inhibiting proteasome function, interfering with the ubiquitin-proteasome pathway, and blocking the degradation of key signaling proteins within tumor cells. Preclinical studies have shown its significant inhibitory effect on tumors such as multiple myeloma.

When used for multiple myeloma, this product can be combined with melphalan and prednisone (MP regimen) for previously untreated patients who are not suitable for high-dose chemotherapy and bone marrow transplantation; or as a monotherapy for patients who have relapsed after receiving at least one or more treatments.

When used for mantle cell lymphoma, this product can be combined with rituximab, cyclophosphamide, doxorubicin, and prednisone for previously untreated adult patients who are not eligible for hematopoietic stem cell transplantation; or for the treatment of relapsed or refractory patients (who have received at least one treatment prior to using this product).

The launch of this product will further enrich the treatment options for multiple myeloma and mantle cell lymphoma in China, providing patients with high-quality and accessible generic drug options and effectively reducing the disease burden.

https://bydrug.pharmcube.com/news/detail/b8877b0680108d8d7560ac97376a9202